
Congrès
Documents du congrès
Accéder aux résumés, posters et présentations présentés aux congrès suivants
Juin 2022
World Congress on Gastrointestinal Cancer (Congrès mondial sur le cancer gastrointestinal) (WCGI)
World Congress on Gastrointestinal Cancer (Congrès mondial sur le cancer gastrointestinal) (WCGI)
Juin 2022 (Barcelone, Espagne)
Posters
Subgroup analysis of the number of prior lines of systemic therapy and clinical outcomes associated with tislelizumab in patients with previously treated advanced hepatocellular carcinoma
Tislelizumab monotherapy for patients with previously treated advanced hepatocellular carcinoma: RATIONALE-208 Chinese subpopulation
Résumés
RATIONALE-306: randomized, multi-regional, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for locally advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC)
Subgroup analysis of the number of prior lines of systemic therapy and clinical outcomes associated with tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC)
Tislelizumab monotherapy for patients with previously treated advanced hepatocellular carcinoma (HCC): RATIONALE-208 Chinese subpopulation
Juin 2022
Asian Oncology Society (AOS)
Asian Oncology Society (AOS)
June 2022 (Seoul, Korea)
Juin 2022
European Hematology Association (Association européenne d’hématologie) (EHA)
European Hematology Association (Association européenne d’hématologie) (EHA)
June 2022 (Vienna, Austria)
Posters
A phase 1 first‑In‑human study of BGB‑16673, a Bruton tyrosine kinase protein degrader, in patients with B‑cell malignancies (trial in progress)
A phase 1 study with the novel BCL2 Inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long‑term follow‑up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
Health-related quality of life outcomes associated with zanubrutinib vs ibrutinib monotherapy in patients with relapsed/refractory (RR) CLL/SLL: results from the randomized phase 3 ALPINE trial
Patient-reported outcomes from a phase 3 randomized study of zanubrutinib vs bendamustine plus rituximab (BR) in patients with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme data set
Preliminary safety and efficacy of BGB‑11417, a potent and selective B‑cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia
Real world evidence of impact of atrial fibrillation on clinical and economic outcomes in patients with chronic lymphocytic leukemia
Real-world treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma
Real-world treatment patterns and economic burden of patients with marginal zone lymphoma
Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia
Tislelizumab, a PD‑1 inhibitor for relapsed/refractory mature (NK)/T‑cell neoplasms: results from a phase 2 study
Zanubrutinib in older patients with relapsed/refractory marginal zone lymphoma (MZL): subgroup analysis of the Magnolia study
Résumés
A phase 1 first in-human study of BGB-16673, a Bruton tyrosine kinase protein degrader, in patients (pts) with B-cell malignancies (trial in progress)
A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with B-cell malignancies: preliminary data
Efficacy of first-line treatment for chronic lymphocytic leukemia: a bayesian network meta-analysis
Health-related quality of life outcomes associated with zanubrutinib vs ibrutinib monotherapy in patients with relapsed/refractory (RR) CLL/SLL: results from the randomized phase 3 ALPINE trial
Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia
Patient-reported outcomes from a phase 3 randomized study of zanubrutinib versus bendamustine plus rituximab (BR) in patients with treatment-naïve (TN) CLL/SLL
Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme dataset
Population-wide patterns of care in mantle cell lymphoma in Australia: an analysis of the pharmaceutical benefits scheme dataset
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients (pts) with acute myeloid leukemia (AML)
Real world evidence of impact of atrial fibrillation on clinical and economic outcomes in patients with chronic lymphocytic leukemia
Real-world treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma
Real-world treatment patterns and economic burden of patients with marginal zone lymphoma
Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia
Treatment persistence and adherence to ibrutinib in patients with Waldenstrӧm macroglobulinemia: a German claims data analysis
Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies
Zanubrutinib in older patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): subgroup analysis of the MAGNOLIA study
Juin 2022
American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)
American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)
June 2022 (Chicago, Illinois, United States)
Présentations
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
RATIONALE-309: updated PFS, PFS2, and OS from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic nasopharyngeal cancer
Posters
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
AdvanTIG-206: anti-TIGIT monoclonal antibody ociperlimab + anti-PD-1 monoclonal antibody tislelizumab + BAT1706 vs tislelizumab + BAT1706 as first-line treatment for unresectable hepatocellular carcinoma
Clinical outcomes associated with tislelizumab in patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib or lenvatinib in RATIONALE-208
Tislelizumab, a PD‑1 inhibitor for relapsed/refractory mature (NK)/T‑cell neoplasms: results from a phase 2 study
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: preliminary results from a phase 1b/2 study
Zanidatamab, a HER2-targeted bispecific antibody, in combination with tislelizumab and chemotherapy as first-line therapy for patients with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma: preliminary results from a phase 1b/2 study
Zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma: primary analysis of the phase 2 randomized ROSEWOOD trial
Résumés
A phase 2 expanded access study of zanubrutinib (ZANU) in patients (pts) with Waldenström Macroglobulinemia (WM)
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM)
AdvanTIG-206: anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus TIS plus BAT1706 as first-line (1L) treatment for advanced hepatocellular carcinoma (HCC)
Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208
Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208
Efficacy of first-line treatment for chronic lymphocytic leukemia: a Bayesian network meta-analysis
Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia
Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme dataset
Population-wide patterns of care in mantle cell lymphoma in Australia: an analysis of the pharmaceutical benefits scheme dataset
Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (ESCC), RATIONALE 302: Asia subgroup
Real world evidence of impact of atrial fibrillation (AF) on clinical and economic outcomes in patients with chronic lymphocytic leukemia (CLL)
Real-world (RW) treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors (BTKi) in patients (pts) with mantle cell lymphoma (MCL)
Real-world treatment (tx) patterns and economic burden of patients (pts) with marginal zone lymphoma (MZL)
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQoL)
Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: results from a phase 2 study
Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): preliminary results from a phase 1b/2 study
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: preliminary results from a phase 1b/2 study
Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial
Mai 2022
International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats) (ISPOR-EU)
International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats) (ISPOR-EU)
May 2022 (Washington, DC, United States)
Mai 2022
International Conference on Clinical and Experimental Hematology (ICCEH)
International Conference on Clinical and Experimental Hematology (ICCEH)
May 2022 (Lublin, Poland)
Avril 2022
Transplantation & Cellular Therapy (TCT)
Transplantation & Cellular Therapy (TCT)
April 2022 (Salt Lake City, Utah, United States)
Avril 2022
American Society of Clinical Oncology Plenary Series Program (ASCO)
American Society of Clinical Oncology Plenary Series Program (ASCO)
Avril 2022 (virtuel)
Avril 2022
American Association for Cancer Research (Association américaine de recherche sur le cancer) (AACR)
American Association for Cancer Research (Association américaine de recherche sur le cancer) (AACR)
Avril 2022 (Nouvelle Orléans, Louisiane, États-Unis)
Posters
BGB-15025, a potent and selective HPK1 inhibitor, is efficacious as a single agent or in combination with PD-1 antibody in multiple tumor models
Co-enrichment of CD8 T-cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors
Pamiparib as a non-P-glycoprotein substrate PARP inhibitor can overcome ABCB1-mediated multidrug resistance in ovarian cancer cells
Prediction of intratumoral TIGIT receptor occupancy after treatment with anti-TIGIT antibodies
RATIONALE 304: tislelizumab plus chemotherapy versus chemotherapy alone as first‑line treatment for non-squamous NSCLC in patients aged 65-75 years
RATIONALE-304: the association of tumor mutational burden with clinical outcomes of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-squamous non-small cell lung cancer
The combination of hyperamplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab
Tislelizumab versus docetaxel in patients with previously treated advanced non-squamous (non-sq) non-small cell lung cancer (NSCLC): subanalysis from the RATIONALE-303 phase 3 randomized clinical study
Tislelizumab versus docetaxel in patients with previously treated advanced squamous (sq) non-small cell lung cancer (NSCLC): subanalysis from phase 3 RATIONALE-303 randomized clinical study
Résumés
BGB-15025, a potent and selective HPK1 inhibitor, is efficacious as a single agent or in combination with PD-1 antibody in multiple tumor models
CD8 T cells and macrophage abundances associated with clinical benefit of tislelizumab in various tumor types
Pamiparib as a non-P-glycoprotein substrate PARP inhibitor can overcome ABCB1-mediated multidrug resistance in ovarian cancer cells
Prediction of intratumoral TIGIT receptor occupancy after the treatment with anti-TIGIT antibodies
RATIONALE 304: tislelizumab (TIS) plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for non-squamous (non-sq) NSCLC in patients (pts) aged 65–75 years
RATIONALE-304: the association of tumor mutational burden (TMB) with clinical outcomes of tislelizumab (TIS) + chemotherapy (chemo) versus chemo alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC)
The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab
Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced non-squamous (non-sq) non-small-cell lung cancer (NSCLC): subanalysis from the RATIONALE-303 phase 3 randomized clinical study
Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced squamous (sq) non-small-cell lung cancer (NSCLC): sub-analysis from phase 3 RATIONALE-303 randomized clinical study
Avril 2022
British Society for Haematology (Société britannique d’hématologie) (BSH)
British Society for Haematology (Société britannique d’hématologie) (BSH)
Avril 2022 (Manchester, Royaume-Uni)
Posters
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma
Résumés
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma
MARS 2022
Italian Society of Experimental Hematology (Société italienne d’hématologie expérimentale) (SIES)
Italian Society of Experimental Hematology (Société italienne d’hématologie expérimentale) (SIES)
Mars 2022 (Rome, Italie)
MARS 2022
Korean Society of Hematology (Société coréenne d'hématologie) (KSH)
Korean Society of Hematology (Société coréenne d'hématologie) (KSH)
March 2022 (Seoul, South Korea)
MARS 2022
European Lung Cancer Congress (Congrès européen pour le cancer du poumon) (ELCC)
European Lung Cancer Congress (Congrès européen pour le cancer du poumon) (ELCC)
Mars 2022 (virtuel)
Posters
AdvanTIG-204: anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab plus concurrent chemoradiotherapy in patients with untreated limited-stage small cell lung cancer
RATIONALE-307: safety analysis of patients receiving tislelizumab plus chemotherapy versus chemotherapy alone in advanced squamous NSCLC
Résumés
AdvanTIG-204: anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus anti-PD-1 mAb tislelizumab (TIS) plus concurrent chemoradiotherapy (cCRT) in patients (pts) with untreated limited-stage small cell lung cancer (LS-SCLC)
RATIONALE-307: safety analysis of patients (pts) receiving tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone in advanced squamous (sq) NSCLC
MARS 2022
French Society of Hematology (Société française d’hématologie) (SFH)
French Society of Hematology (Société française d’hématologie) (SFH)
Mars 2022 (Paris, France)
MARS 2022
Society of Gynecologic Oncology (Société d’oncologie gynécologique) (SGO)
Society of Gynecologic Oncology (Société d’oncologie gynécologique) (SGO)
Mars 2022 (Phoenix, Arizona, États-Unis)
Posters
AdvanTIG-202: a phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer
Phase 2 study of tislelizumab monotherapy in previously-treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors: gynecological cancer subgroup
Résumés
AdvanTIG-202: a phase 2 study investigating anti-T cell immunoglobulin and ITIM domain monoclonal antibody ociperlimab plus tislelizumab in patients with previously treated recurrent or metastatic cervical cancer
Phase 2 study of tislelizumab monotherapy in previously treated, locally advanced, unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors: gynecological cancer subgroup
MARS 2022
Francophone Days of Hepato-gastroenterology and Digestive Oncology (Journées francophones d’hépato-gastroentérologie et d’oncologie digestive) (JFHOD)
Francophone Days of Hepato-gastroenterology and Digestive Oncology (Journées francophones d’hépato-gastroentérologie et d’oncologie digestive) (JFHOD)
Mars 2022 (Paris, France)
MARS 2022
European Society of Medical Oncology Targeted Anticancer Therapies (Société européenne d’oncologie médicale, thérapies anticancéreuses ciblées) (ESMO-TAT)
European Society of Medical Oncology Targeted Anticancer Therapies (Société européenne d’oncologie médicale, thérapies anticancéreuses ciblées) (ESMO-TAT)
Mars 2022 (virtuel)
Posters
Février 2022
Japanese Society of Medical Oncology (Société japonaise d’oncologie médicale) (JSMO)
Japanese Society of Medical Oncology (Société japonaise d’oncologie médicale) (JSMO)
Février 2022 (Kyoto, Japon)
Janvier 2022
British Thoracic Oncology Group (groupe d’oncologie thoracique britannique) (BTOG)
British Thoracic Oncology Group (groupe d’oncologie thoracique britannique) (BTOG)
Janvier 2022 (virtuel)
Janvier 2022
American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers gastro-intestinaux) (ASCO-GI)
American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers gastro-intestinaux) (ASCO-GI)
Janvier 2022 (San Francisco, Californie, États-Unis)
Posters
AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma expressing programmed death-ligand 1 (PD-L1)
AdvanTIG-206: anti-TIGIT monoclonal antibody ociperlimab + anti-PD-1 monoclonal antibody tislelizumab + BAT1706 vs tislelizumab + BAT1706 as first-line treatment for unresectable hepatocellular carcinoma
Clinical outcomes associated with tislelizumab in patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib or lenvatinib in RATIONALE-208
Clinical outcomes in patients with previously treated advanced hepatocellular carcinoma experiencing hepatitis B virus DNA increases during tislelizumab treatment in RATIONALE-208
DKN-01 and tislelizumab ± chemotherapy as first-line (1L) or second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life
Updated analysis from a phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors
Résumés
AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1)
AdvanTIG-206: anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein-1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 vs TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC)
Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208
Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208
DKN-01 and tislelizumab ± chemotherapy as first-line (1L) or second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC)
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC)
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQoL)
Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors
Décembre 2021
American Society of Hematology (Société américaine d’hématologie) (ASH)
American Society of Hematology (Société américaine d’hématologie) (ASH)
Décembre 2021 (Atlanta, Géorgie, États-Unis)
Présentations
Factors associated with treatment among older adults diagnosed with chronic lymphocytic leukemia: an analysis using Medicare claims data
Impact of atrial fibrillation on cardiovascular and economic outcomes in patients with chronic lymphocytic leukemia
Phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients with relapsed/refractory B-cell malignancies
Preliminary safety and efficacy data from patients with relapsed/refractory B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 in monotherapy or in combination with zanubrutinib
Productivity loss and indirect costs among non-Hodgkin lymphoma patients and their caregivers
Real-world Bruton tyrosine kinase inhibitor treatment patterns, compliance, costs, and hospitalizations in patients with mantle cell lymphoma in the United States
Real-world disease burden, costs and resource utilization of hospital-based care among mantle cell lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma and chronic lymphocytic leukemia: disparities and risk factors
Real-world testing patterns for risk assessment and implications on the adoption of novel therapeutics in chronic lymphocytic leukemia: IGHV mutation status, FISH cytogenetic, and immunophenotyping
Real-world treatment patterns, adherence and healthcare resource utilization for chronic lymphocytic leukemia/small lymphocytic lymphoma among veterans in the United States
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma
Zanubrutinib in combination with venetoclax for patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma with del(17p): early results from Arm D of the SEQUOIA (BGB-3111-304) trial
Posters
Factors associated with treatment among older adults diagnosed with chronic lymphocytic leukemia: an analysis using Medicare claims data
Impact of atrial fibrillation on cardiovascular and economic outcomes in patients with chronic lymphocytic leukemia
Phase 2 study of zanubrutinib in BTK-inhibitor-intolerant patients with relapsed/refractory B-cell malignancies
Preliminary safety and efficacy data from patients with relapsed/refractory B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 in monotherapy or in combination with zanubrutinib
Productivity loss and indirect costs among non-Hodgkin lymphoma patients and their caregivers
Real-world Bruton tyrosine kinase inhibitor treatment patterns, compliance, costs, and hospitalizations in patients with mantle cell lymphoma in the United States
Real-world disease burden, costs and resource utilization of hospital-based care among mantle cell lymphoma, Waldenstrӧm macroglobulinemia, marginal zone lymphoma and chronic lymphocytic leukemia: disparities and risk factors
Real-world testing patterns for risk assessment and implications on the adoption of novel therapeutics in chronic lymphocytic leukemia: IGHV mutation status, FISH cytogenetic, and immunophenotyping
Real-world treatment patterns, adherence and healthcare resource utilization for chronic lymphocytic leukemia/small lymphocytic lymphoma among veterans in the United States
Résumés
Factors associated with treatment among older adults diagnosed with chronic lymphocytic leukemia: an analysis using Medicare claims data
Impact of atrial fibrillation on cardiovascular and economic outcomes in patients with chronic lymphocytic leukemia
Phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients (pts) with relapsed/refractory B-cell malignancies
Preliminary safety and efficacy data from patients (pts) with relapsed/refractory (R/R) B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 in monotherapy or in combination with zanubrutinib
Productivity loss and indirect costs among non-Hodgkin lymphoma patients and their caregivers
Real-world Bruton tyrosine kinase inhibitor treatment patterns, compliance, costs, and hospitalizations in patients with mantle cell lymphoma in the United States
Real-world disease burden, costs and resource utilization of hospital-based care among mantle cell lymphoma, Waldenstrӧm macroglobulinemia, marginal zone lymphoma and chronic lymphocytic leukemia: disparities and risk factors
Real-world testing patterns for risk assessment and implications on the adoption of novel therapeutics in chronic lymphocytic leukemia: IGHV mutation status, FISH cytogenetic, and immunophenotyping
Real-world treatment patterns, adherence and healthcare resource utilization for chronic lymphocytic leukemia/small lymphocytic lymphoma among veterans in the United States
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Zanubrutinib in combination with venetoclax for patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): early results from Arm D of the SEQUOIA (BGB-3111-304) trial
Décembre 2021
European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)
European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)
Décembre 2021 (Genève, Suisse)
Posters
AdvanTIG-301: anti-TIGIT monoclonal antibody ociperlimab + tislelizumab + concurrent chemoradiotherapy followed by ociperlimab + tislelizumab or tislelizumab + concurrent chemoradiotherapy followed by tislelizumab versus concurrent chemoradiotherapy followed by durvalumab in previously untreated, locally advanced, unresectable non-small cell lung cancer
Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study
Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer
Résumés
AdvanTIG-301: anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) + tislelizumab (TIS) + concurrent chemoradiotherapy (cCRT) followed by OCI + TIS or TIS + cCRT followed by TIS vs cCRT followed by durvalumab (DUR) in previously untreated, locally advanced, unresectable NSCLC
RATIONALE 309: a randomized, global, double-blind, phase 3 trial of tislelizumab (TIS) vs placebo, plus gemcitabine + cisplatin (GP), as 1L treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC)
Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)
Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1-refractory/resistant unresectable or metastatic melanoma from a phase 1b study
Décembre 2021
Immunotherapy Bridge (IBC)
Immunotherapy Bridge (IBC)
Décembre 2021 (virtuel)
Novembre 2021
International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats - Europe) (ISPOR-EU)
International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats - Europe) (ISPOR-EU)
Novembre 2021 (virtuel)
Posters
Novembre 2021
Australasian Melanoma Conference (Conférence australasienne sur le mélanome) (AMC)
Australasian Melanoma Conference (Conférence australasienne sur le mélanome) (AMC)
Novembre 2021 (Sydney, Australie)
Novembre 2021
Clinical Oncology Society of Australia (Société d’oncologie clinique d’Australie) (COSA)
Clinical Oncology Society of Australia (Société d’oncologie clinique d’Australie) (COSA)
Novembre 2021 (Melbourne, Australie)
Novembre 2021
Portuguese Society of Hematology (Société portugaise d’hématologie) (SPH)
Portuguese Society of Hematology (Société portugaise d’hématologie) (SPH)
Novembre 2021 (Espinho, Portugal)
Présentations
Novembre 2021
Society for Immunotherapy of Cancer (Société d’immunothérapie pour le cancer) (SITC)
Society for Immunotherapy of Cancer (Société d’immunothérapie pour le cancer) (SITC)
Novembre 2021 (Washington, DC, États-Unis)
Posters
Association of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with clinical outcomes to tislelizumab monotherapy in patients with previously treated advanced hepatocellular carcinoma
Association of tumor mutation burden and genomic alterations with clinical outcomes in Chinese patients with advanced solid tumors treated with tislelizumab
Tumor-immune signatures associated with response or resistance to tislelizumab in patients with previously treated advanced hepatocellular carcinoma
Résumés
Association of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with clinical outcomes to tislelizumab monotherapy in patients with previously treated advanced hepatocellular carcinoma
Association of tumor mutation burden (TMB) and genomic alterations (GA) with clinical outcomes in Chinese patients with advanced solid tumors treated with tislelizumab
Tumor-immune signatures associated with response or resistance to tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC)
Octobre 2021
Italian Society of Hematology (Société italienne d’hématologie) (SIE)
Italian Society of Hematology (Société italienne d’hématologie) (SIE)
Octobre 2021 (Milan, Italie)
Présentations
ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM)
Safety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA phase 2 study)
Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenström macroglobulinemia (WM)
Résumés
ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrӧm macroglobulinemia
Safety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA phase 2 study)
Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenstrӧm macroglobulinemia (WM)
Octobre 2021
Academy of Managed Care Pharmacy Nexus (Nexus Académie de gestion pharmaceutique des soins) (AMCP Nexus)
Academy of Managed Care Pharmacy Nexus (Nexus Académie de gestion pharmaceutique des soins) (AMCP Nexus)
Octobre 2021 (Denver, Colorado, États-Unis)
Posters
Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenstrӧm macroglobulinemia in the United States
Real-world treatment pattern, adherence, cost and healthcare resource utilization of commercially-insured patients with Waldenstrӧm macroglobulinemia in the United States
Zanubrutinib versus ibrutinib to treat adult patients with Waldenstrӧm macroglobulinemia: a cost per response model from a payer perspective in the United States
Résumés
Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenstrӧm macroglobulinemia in the United States
Real-world treatment pattern, adherence, cost and healthcare resource utilization of commercially-insured patients with Waldenstrӧm macroglobulinemia in the United States
Zanubrutinib versus ibrutinib to treat adult patients with Waldenstrӧm macroglobulinemia: a cost per response model from a payer perspective in the United States
Octobre 2021
Spanish Society of Medical Oncology (Société espagnole d’oncologie médicale) (SEOM)
Spanish Society of Medical Oncology (Société espagnole d’oncologie médicale) (SEOM)
Octobre 2021 (virtuel)
Octobre 2021
Spanish Society of Hematology and Hemotherapy (Société espagnole d’hématologie et d’hématothérapie) (SEHH)
Spanish Society of Hematology and Hemotherapy (Société espagnole d’hématologie et d’hématothérapie) (SEHH)
Octobre 2021 (Pampelune, Espagne)
Posters
Octobre 2021
Australasian Gastro-Intestinal Trials Group (Groupe australasien d’essais gastro-intestinaux) (AGITG)
Australasian Gastro-Intestinal Trials Group (Groupe australasien d’essais gastro-intestinaux) (AGITG)
Octobre 2021 (virtuel)
Posters
ADVANTIG-105: phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors
RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma
Résumés
AdvanTIG-105: phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors
RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma
Octobre 2021
German, Austrian, and Swiss Societies for Hematology & Medical Oncology (Sociétés allemandes, autrichiennes et suisses d’hématologie et d’oncologie médicale) (DGHO)
German, Austrian, and Swiss Societies for Hematology & Medical Oncology (Sociétés allemandes, autrichiennes et suisses d’hématologie et d’oncologie médicale) (DGHO)
Octobre 2021 (Berlin, Allemagne)
Présentations
Septembre 2021
Society of Hematologic Oncology (Société d’oncologie hématologique) (SOHO)
Society of Hematologic Oncology (Société d’oncologie hématologique) (SOHO)
Septembre 2021 (Rome, Italie)
Posters
ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrӧm macroglobulinemia
Safety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA phase 2 study)
Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type Waldenstrӧm macroglobulinemia
Résumés
ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrӧm macroglobulinemia
Safety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA phase 2 study)
Updated results of the ASPEN trial from a cohort of patients with wild-type MYD88 Waldenstrӧm macroglobulinemia
Septembre 2021
Hematology Society of Australia and New Zealand (Blood) [Société d’hématologie d’Australie et de Nouvelle Zélande (sang)]
Hematology Society of Australia and New Zealand (Blood) [Société d’hématologie d’Australie et de Nouvelle Zélande (sang)]
Septembre 2021 (virtuel)
Septembre 2021
European Society for Medical Oncology (Société européenne d’oncologie médicale) (ESMO)
European Society for Medical Oncology (Société européenne d’oncologie médicale) (ESMO)
Septembre 2021 (virtuel)
Posters
Association between use of antibiotics and clinical outcomes with tislelizumab monotherapy
DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
Effects of tislelizumab monotherapy on health-related quality of life in patients with previously treated unresectable hepatocellular carcinoma
RATIONALE 304: tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for non-squamous non-small cell lung cancer in patients who are smokers vs non-smokers
RATIONALE 307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer in patients who were smokers versus non-smokers
Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic non-small cell lung cancer
Sitravatinib + tislelizumab in patients with metastatic non-small cell lung cancer
Résumés
Association between use of antibiotics (ATB) and clinical outcomes with tislelizumab (tisle) monotherapy
DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
Effects of tislelizumab (TIS) monotherapy on health-related quality of life in patients with previously treated unresectable hepatocellular carcinoma (HCC)
RATIONALE 304: tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone as first‑line (1L) treatment for non-squamous (non-sq) non-small cell lung cancer (NSCLC) in patients (pts) who are smokers vs non-smokers
RATIONALE 307: tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC) in patients (pts) who were smokers vs non-smokers
Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic NSCLC
Sitravatinib + tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC)
Septembre 2021
International Workshop on CLL (Atelier international sur la leucémie lymphoïde chronique) (iwCLL)
International Workshop on CLL (Atelier international sur la leucémie lymphoïde chronique) (iwCLL)
Septembre 2021 (virtuel)
Posters
A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukemia (CLL) in the United States
Zanubrutinib in patients with B-cell malignancies intolerant to ibrutinib and/or acalabrutinib
Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results
Résumés
A real-world study to assess the association of cardiovascular adverse events with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukemia
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Zanubrutinib in patients with B-cell malignancies intolerant to ibrutinib and/or acalabrutinib
Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results
Septembre 2021
Chinese Society of Clinical Oncology (Société chinoise d’oncologie clinique) (CSCO)
Chinese Society of Clinical Oncology (Société chinoise d’oncologie clinique) (CSCO)
Septembre 2021 (virtuel)
Présentations
A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors
A phase II study of the efficacy and safety of tislelizumab plus lenvatinib in patients with advanced or metastatic hepatocellular carcinoma: results of safety run-in period
RATIONALE-307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 years
Results from RATIONALE-303: a global phase 3 study of tislelizumab vs docetaxel as second- or third-line therapy for patients with locally advanced or metastatic NSCLC
Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study
Résumés
A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors
A phase II study of the efficacy and safety of tislelizumab plus lenvatinib in patients with advanced or metastatic hepatocellular carcinoma: results of safety run-in period
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Phase 2 study of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA study)
Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib
RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma
RATIONALE-307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 years
Results from RATIONALE 303: a global phase 3 study of tislelizumab (TIS) vs docetaxel (TAX) as second- or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1-refractory/resistant unresectable or metastatic melanoma from a phase 1b study
Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC)
Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: long-term follow-up efficacy and safety results from a phase 2 study
Zanidatamab (ZW25), a novel anti-HER2 bispecific antibody, monotherapy as second-line treatment for patients (pts) with advanced or metastatic HER2-amplified biliary tract cancer (BTC): a phase 2b trial-in-progress
Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results
Septembre 2021
French Society of Hematology (Société française d’hématologie) (SFH)
French Society of Hematology (Société française d’hématologie) (SFH)
Septembre 2021 (Paris, France)
Présentations
Posters
Résumés
ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM)
Safety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA phase 2 study)
Updated results of the ASPEN trial from a cohort of patients with wild-type MYD88 Waldenström macroglobulinemia (MYD88WT WM)
Septembre 2021
World Congress on Lung Cancer (Congrès mondial sur le cancer du poumon) (WCLC)
World Congress on Lung Cancer (Congrès mondial sur le cancer du poumon) (WCLC)
Septembre 2021 (virtuel)
Posters
RATIONALE 307: a subgroup analysis of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for Stage IIIB advanced squamous NSCLC
RATIONALE-303 phase 3 tislelizumab vs docetaxel in previously treated advanced NSCLC: China subgroup analysis
RATIONALE-307: updated biomarker analysis of phase 3 study of tislelizumab plus chemotherapy vs chemotherapy alone for 1L advanced sq-NSCLC
Résumés
RATIONALE 307: a subgroup analysis of tislelizumab plus chemo vs chemo alone as 1L treatment for Stage IIIB advanced sq NSCLC
RATIONALE-303 phase 3 tislelizumab vs docetaxel in previously treated advanced NSCLC: China subgroup analysis
RATIONALE-307: updated biomarker analysis of phase 3 study of tislelizumab plus chemo vs chemo alone for 1L advanced sq-NSCLC
Septembre 2021
Polish Society of Hematology and Transfusion Medicine (Société polonaise d’hématologie et de médecine transfusionnelle) (PTHiT)
Polish Society of Hematology and Transfusion Medicine (Société polonaise d’hématologie et de médecine transfusionnelle) (PTHiT)
Septembre 2021 (virtuel)
Août 2021
Pan Pacific Lymphoma Conference (Conférence pan-Pacifique du lymphome) (PPLC)
Pan Pacific Lymphoma Conference (Conférence pan-Pacifique du lymphome) (PPLC)
Août 2021 (Big Island, Hawaii)
Juillet 2021
International Symposium of Yonsei Song-dang Institute for Cancer Research (Symposium international de l’Institut Yonsei Song-dang de recherche sur le cancer) (N/A)
International Symposium of Yonsei Song-dang Institute for Cancer Research (Symposium international de l’Institut Yonsei Song-dang de recherche sur le cancer) (N/A)
Juillet 2021 (Séoul, Corée du Sud)
Juin 2021
World Congress on Gastrointestinal Cancer (Congrès mondial sur le cancer gastrointestinal) (WCGI)
World Congress on Gastrointestinal Cancer (Congrès mondial sur le cancer gastrointestinal) (WCGI)
Juin 2021 (virtuel)
Présentations
Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and the Europe/North America subgroup
Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with previously treated advanced hepatocellular carcinoma
Juin 2021
International Conference on Malignant Lymphoma (Conférence internationale sur le lymphome malin) (ICML)
International Conference on Malignant Lymphoma (Conférence internationale sur le lymphome malin) (ICML)
Juin 2021 (virtuel)
Posters
Résumés
Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib
Preliminary safety data from patients (pts) with relapsed/refractory (R/R) B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417
Safety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA phase 2 study)
Juin 2021
European Hematology Association (Association européenne d’hématologie) (EHA)
European Hematology Association (Association européenne d’hématologie) (EHA)
Juin 2021 (virtuel)
Présentations
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: long-term follow-up efficacy and safety results from a phase 2 study
Posters
Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenstrӧm macroglobulinemia
Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenstrӧm macroglobulinemia (WM): matching-adjusted indirect comparisons
Phase 2 study of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA study)
Preliminary results of a phase 2 study of zanubrutinib in patients with previously treated B cell malignancies intolerant to ibrutinib/acalabrutinib
Preliminary safety data from patients with relapsed/refractory (R/R) B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417
Zanubrutinib in patients with relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results
Résumés
Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenstrӧm macroglobulinemia
Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenstrӧm macroglobulinemia: matching-adjusted indirect comparisons
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Phase 2 study of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA study)
Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib
Preliminary safety data from patients (pts) with relapsed/refractory (R/R) B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417
Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: long-term follow-up efficacy and safety results from a phase 2 study
Zanubrutinib (zanu) in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL): long-term efficacy and safety results from a phase 2 study
Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results
Juin 2021
American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)
American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)
Juin 2021 (virtuel)
Posters
A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation
A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors
ADVANTIG-105: phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors
AdvanTIG-202: a phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer
AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma expressing programmed death-ligand 1 (PD-L1)
AdvanTIG-302: anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs pembrolizumab in programmed death ligand 1-selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer
Efficacy and safety of zanubrutinib versus rituximab-based chemotherapy in Waldenstrӧm macroglobulinemia (WM): matching-adjusted indirect comparisons
PARALLEL 303: phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line chemotherapy
RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma
RATIONALE-307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65
The effects of tislelizumab treatment on the health-related quality of life of non−small cell lung cancer patients who progressed on a prior platinum-containing regimen
Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: a phase 1B/2 trial-in-progress
Résumés
A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation
A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors
AdvanTIG-105: phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors
AdvanTIG-202: a phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer
AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1)
AdvanTIG-302: anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) vs pembrolizumab (PEM) in programmed death ligand 1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC)
Cardiac risk factors and adverse events among patients receiving first-line CLL treatment in a real-world community practice setting
Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenström macroglobulinemia in the United States
Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenström macroglobulinemia (WM): matching-adjusted indirect comparisons
PARALLEL 303: phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line (1L) chemotherapy
Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib
RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma
RATIONALE-307: tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65
Real-world treatment patterns, adherence, costs and healthcare resource utilization associated with Waldenström macroglobulinemia in the United States
The effects of tislelizumab treatment on the health-related quality of life of non-small cell lung cancer patients who progressed on a prior platinum-containing regimen
Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical hodgkin lymphoma (cHL): long-term follow-up efficacy and safety results from a phase 2 study
Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: a phase 1B/2 trial-in-progress
Mai 2021
International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats) (ISPOR-EU)
International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats) (ISPOR-EU)
Mai 2021 (virtuel)
Posters
Examining longitudinal practice patterns in the use of anti-PD-1 and anti-PD-L1 inhibitors as first-line therapy in non-small cell lung cancer patients in the US
Health related quality of life (HRQOL) review in patients with ovarian cancer: a systematic literature review (SLR)
Psychometric validation of the EORTC QLQ-HCC18 in patients with previously treated unresectable hepatocellular carcinoma
Résumés
Examining longitudinal practice patterns in the use of anti-PD-1 and anti-PD-L1 inhibitors as first-line therapy in non-small cell lung cancer patients in the US
Health related quality of life (HRQOL) review in patients with ovarian cancer: a systematic literature review (SLR)
Psychometric validation of the EORTC QLQ-HCC18 in patients with previously treated unresectable hepatocellular carcinoma
Avril 2021
American Association for Cancer Research (Association américaine de recherche sur le cancer) (AACR)
American Association for Cancer Research (Association américaine de recherche sur le cancer) (AACR)
Avril 2021 (virtuel)
Présentations
Results from RATIONALE 303: a global phase 3 study of tislelizumab vs docetaxel as second- or third-line therapy for patients with locally advanced or metastatic NSCLC
Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study
Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC)
Résumés
A Fc-competent anti-human TIGIT blocking antibody BGB-A1217 elicits strong immune responses and potent anti-tumor efficacy in pre-clinical models
Results from RATIONALE 303: a global phase 3 study of tislelizumab (TIS) vs docetaxel (TAX) as second- or third-line therapy for patients with locally advanced or metastatic NSCLC
Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study
Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC)
Mars 2021
European Lung Cancer Congress (Congrès européen pour le cancer du poumon) (ELCC)
European Lung Cancer Congress (Congrès européen pour le cancer du poumon) (ELCC)
Mars 2021 (virtuel)
Mars 2021
Japanese Gastric Cancer Association (Association japonaise pour le cancer gastrique) (JGCA)
Japanese Gastric Cancer Association (Association japonaise pour le cancer gastrique) (JGCA)
Mars 2021 (virtuel)
Janvier 2021
American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers gastro-intestinaux) (ASCO-GI)
American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers gastro-intestinaux) (ASCO-GI)
Janvier 2021 (virtuel)
Décembre 2020
European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)
European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)
Décembre 2020 (virtuel)
Décembre 2020
American Society of Hematology (Société américaine d’hématologie) (ASH)
American Society of Hematology (Société américaine d’hématologie) (ASH)
Décembre 2020 (virtuel)
Présentations
Posters
A clinical practice comparison of overall survival, time-to-next-treatment, and time-to-treatment-discontinuation among CLL/SLL patients receiving first-line ibrutinib with and without a del(17p) mutation
Earlier use of zanubrutinib monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma is associated with greater efficacy: A pooled analysis from 3 studies
Efficacy and safety of zanubrutinib in patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): Follow-up results from Arm C of the SEQUOIA (BGB-3111-304) trial
Safety and efficacy of the Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in patients with Waldenström macroglobulinemia from a Phase 2 trial
Tumor microenvironment associated with complete response to tislelizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma reveals a potentially different mechanism of action
Zanubrutinib in combination with venetoclax for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) trial
Résumés
A clinical practice comparison of overall survival, time-to-next-treatment, and time-to-treatment-discontinuation among CLL/SLL patients receiving first-line ibrutinib with and without a del(17p) mutation
Earlier use of zanubrutinib monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma is associated with greater efficacy: A pooled analysis from 3 studies
Efficacy and safety of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma: Initial results of the MAGNOLIA (BGB-3111-214) trial
Efficacy and safety of zanubrutinib in patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): Follow-up results from Arm C of the SEQUOIA (BGB-3111-304) trial
Phase 2 study of zanubrutinib in patients with relapsed/refractory B-cell malignancies intolerant to ibrutinib/acalabrutinib
Safety and efficacy of the Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in patients with Waldenström macroglobulinemia from a Phase 2 trial
Tumor microenvironment associated with complete response to tislelizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma reveals a potentially different mechanism of action
Zanubrutinib in combination with venetoclax for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) trial
Novembre 2020
Society for Neuro - Oncology (Société de neuro-oncologie) (SNO)
Society for Neuro - Oncology (Société de neuro-oncologie) (SNO)
Novembre 2020 (virtuel)
Novembre 2020
International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats - Europe) (ISPOR-EU)
International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats - Europe) (ISPOR-EU)
Novembre 2020 (virtuel)
Posters
A systematic literature review of pharmacoeconomic evaluations for chronic lymphocytic leukemia in Europe
Budget impact analysis of zanubrutinib for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy from the payer perspective in the United States
Healthcare costs and resource utilization associated with PARP Inhibitors in ovarian cancer patients initially treated with platinum-based therapy
Use of PD-1/PD-L1 inhibitors after first-line therapy in esophageal cancer patients in the US
Résumés
A systematic literature review of pharmacoeconomic evaluations for chronic lymphocytic leukemia in Europe
Budget impact analysis of zanubrutinib for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy from the payer perspective in the United States
Healthcare costs and resource utilization associated with PARP inhibitors in ovarian cancer patients initially treated with platinum-based therapy
Use of PD-1/PD-L1 inhibitors after first-line therapy in esophageal cancer patients in the US
Novembre 2020
Society for Immunotherapy of Cancer (Société d’immunothérapie pour le cancer) (SITC)
Society for Immunotherapy of Cancer (Société d’immunothérapie pour le cancer) (SITC)
Novembre 2020 (virtuel)
Posters
A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models
Association between programmed death-ligand 1 expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma
Potential mechanisms of resistance identified through analysis of multiple biomarkers in immune-hot non-responders with non-small cell lung cancer treated with tislelizumab
T-cell-, MHC I-, and tumor-related gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1-high urothelial carcinoma
Tumor-immune signatures associated with response or resistance to tislelizumab (anti-PD-1) in esophageal squamous cell carcinoma (ESCC)
Résumés
A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models
Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)
Potential mechanisms of resistance identified through analysis of multiple biomarkers in immune hot non-responders with non-small cell lung cancer (NSCLC) treated with tislelizumab
T-cell, MHC I, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma
Tumor-immune signatures associated with response or resistance to tislelizumab (anti-PD-1) in esophageal squamous cell carcinoma (ESCC)
Octobre 2020
North America Conference on Lung Cancer (Conférence d’Amérique du Nord pour le cancer du poumon) (NACLC)
North America Conference on Lung Cancer (Conférence d’Amérique du Nord pour le cancer du poumon) (NACLC)
Octobre 2020 (virtuel)
Posters
Efficacy and safety data from a phase 1/2 trial of tislelizumab in Chinese patients with non-small cell lung cancer
Examining the impact of tislelizumab added to platinum-doublet chemotherapy on health-related quality of life in patients with nonsquamous NSCLC
Tislelizumab plus standard chemotherapy and health-related quality of life in patients with advanced squamous non-small cell lung cancer
Résumés
Efficacy and safety data from a phase 1/2 trial of tislelizumab in Chinese patients with non-small cell lung cancer (NSCLC)
Examining the impact of tislelizumab added to platinum-doublet chemotherapy on health-related quality of life in patients with non-squamous NSCLC
Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer
Tislelizumab plus standard chemotherapy for treatment of advanced squamous non-small cell lung cancer: patients' health related quality of life
Septembre 2020
Chinese Society of Clinical Oncology (Société chinoise d’oncologie clinique) (CSCO)
Chinese Society of Clinical Oncology (Société chinoise d’oncologie clinique) (CSCO)
Septembre 2020 (virtuel)
Présentations
RATIONALE 304: tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous non-small cell lung cancer (nsq-NSCLC)
RATIONALE 307: phase 3 study of tislelizumab plus chemotherapy vs chemotherapy alone as first‑line treatment for advanced squamous non‑small cell lung cancer
Résumés
ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM)
Neoadjuvant tislelizumab or placebo plus platinum-based chemotherapy followed by adjuvant tislelizumab or placebo in patients with resectable non‑small cell lung cancer (NSCLC): a phase 3 trial in progress
Phase 3 trial in progress: tislelizumab plus cisplatin/carboplatin and gemcitabine versus placebo plus cisplatin/carboplatin and gemcitabine in Chinese patients with advanced urothelial carcinoma
Phase 3 trial in progress: tislelizumab vs placebo in combination with concurrent chemoradiotherapy (cCRT) in patients with localized esophageal squamous cell carcinoma (ESCC)
Platinum-containing combination chemotherapy with or without tislelizumab as first-line therapy in patients with extensive-stage small cell lung cancer: A phase 3 trial in progress
RATIONALE 304: tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous non-small cell lung cancer (nsq-NSCLC)
RATIONALE 307: phase 3 study of tislelizumab plus chemotherapy vs chemotherapy alone as first‑line (1L) treatment for advanced squamous non‑small cell lung cancer (sq NSCLC)
Tislelizumab + chemotherapy versus placebo + chemotherapy in Chinese patients with recurrent or metastatic nasopharyngeal cancer: a phase 3 trial-in-progress
Tislelizumab in Chinese patients with non-small cell lung cancer (NSCLC)
Tislelizumab plus standard chemotherapy and health-related quality of life In patients with advanced squamous non-small cell lung cancer
Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenström macroglobulinemia (WM)
Zanubrutinib (BGB-3111) in combination with rituximab in patients with relapsed/refractory non-Hodgkin lymphoma
Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase 2, single-arm, multicenter, study
Septembre 2020
European Society for Medical Oncology (Société européenne d’oncologie médicale) (ESMO)
European Society for Medical Oncology (Société européenne d’oncologie médicale) (ESMO)
Septembre 2020 (virtuel)
Présentations
BGB-A333, an anti-PD-L1 monoclonal antibody, in combination with tislelizumab in patients with urothelial carcinoma
Clinical benefit in biomarker-positive patients with locally advanced or metastatic solid tumors treated with the PARP 1/2 inhibitor pamiparib in combination with low-dose temozolomide
Posters
Investigation of PD-L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with VENTANA PD-L1 (SP263) assay and combined positive score (CPS)
Phase 2 study of pamiparib in Chinese patients with advanced ovarian cancer
Safety and efficacy of long-term exposure (LTE) to tislelizumab in Chinese patients with advanced solid tumors
Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment in locally advanced/metastatic non-squamous NSCLC
Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer
Résumés
BGB-A333, an anti-PD-L1 monoclonal antibody, in combination with tislelizumab in patients with urothelial carcinoma
Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumors treated with the PARP 1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ)
Investigation of PD-L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with VENTANA PD-L1 (SP263) assay and combined positive score (CPS)
Phase 2 study of pamiparib in Chinese patients (pts) with advanced ovarian cancer (aOC)
Safety and efficacy of long-term exposure (LTE) to tislelizumab in Chinese patients with advanced solid tumors
Tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC (nsq-NSCLC)
Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer (SQ NSCLC)
Septembre 2020
Association of VA Hematology/Oncology (Association d’hématologie/oncologie VA) (AVAHO)
Association of VA Hematology/Oncology (Association d’hématologie/oncologie VA) (AVAHO)
Septembre 2020 (virtuel)
Posters
Juillet 2020
World Congress on Gastrointestinal Cancer (Congrès mondial sur le cancer gastrointestinal) (WCGI)
World Congress on Gastrointestinal Cancer (Congrès mondial sur le cancer gastrointestinal) (WCGI)
Juin 2020 (virtuel)
Juin 2020
American Association for Cancer Research (Association américaine de recherche sur le cancer) (AACR)
American Association for Cancer Research (Association américaine de recherche sur le cancer) (AACR)
Juin 2020 (virtuel)
Posters
BGB-10188, a highly selective PI3Kδ inhibitor with improved safety profile and superior anti-tumor activities in vivo
Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior anti-tumour activities in haematological tumour models
Preliminary safety and efficacy data of BGB-A333, an anti-PD-L1 monoclonal antibody, alone and in combination with tislelizumab in patients with advanced solid tumors
RAF dimer inhibitor lifirafenib enhances the antitumor activity of MEK inhibitor mirdametinib in RAS mutant tumors
Résumés
BGB-10188, a highly selective PI3Kδ inhibitor with improved safety profile and superior anti-tumor activities in vivo
Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior anti-tumor activities in haematological tumour models
Preliminary safety and efficacy data of BGB-A333, an anti-PD-L1 monoclonal antibody, alone and in combination with tislelizumab in patients with advanced solid tumors
RAF dimer inhibitor lifirafenib enhances the antitumor activity of MEK inhibitor mirdametinib in RAS mutant tumors
Juin 2020
European Hematology Association (Association européenne d’hématologie) (EHA)
European Hematology Association (Association européenne d’hématologie) (EHA)
Juin 2020 (virtuel)
Présentations
Posters
Biomarker identification in relapsed/refractory non-germinal center B-cell-like diffuse large B-cell lymphoma treated with zanubrutinib
Outcomes of relapsed/refractory MCL patients treated with zanubrutinib monotherapy in the second line and in later lines: a pooled analysis from 2 studies
Phase 1/2 study of single-agent zanubrutinib in patients with relapsed/refractory marginal zone lymphoma
Tislelizumab (BGB-A317) for relapsed/refractory extranodal NK/T-cell lymphoma: preliminary efficacy and safety results from a phase 2 study
Tislelizumab (BGB-A317) for relapsed/refractory peripheral T-cell lymphoma: safety and efficacy results from a phase 2 study
Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type Waldenstrom macroglobulinemia
Zanubrutinib (BGB-3111) in combination with rituximab in patients with relapsed/refractory non-Hodgkin lymphoma
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: three years of follow‑up
Résumés
ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrom macroglobulinemia (WM)
Biomarker identification in relapsed/refractory non-germinal center B-cell like diffuse large B-cell lymphoma treated with zanubrutinib
Outcomes of relapsed/refractory MCL patients treated with zanubrutinib monotherapy in the second line and in later lines: a pooled analysis from 2 studies
Phase 1/2 study of single-agent zanubrutinib in patients with relapsed/refractory marginal zone lymphoma
Three-year follow-up of treatment-naive and previously treated patients with Waldenstrom macroglobulinemia (WM) recieving single agent zanubrutinib
Tislelizumab (BGB-A317) for relapsed/refractory extranodal NK/T-cell lymphoma: preliminary efficacy and safety results from a phase 2 study
Tislelizumab (BGB-A317) for relapsed/refractory peripheral T-cell lymphomas: safety and efficacy results from a phase 2 study
Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type Waldenstrom macroglobulinemia
Zanubrutinib (BGB-3111) in combination with rituximab in patients with relapsed/refractory non-Hodgkin lymphoma
Mai 2020
American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)
American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)
Mai 2020 (virtuel)
Posters
A phase 3, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma who are ineligible for stem cell transplantation
Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma
BGB-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody in patients with advanced solid tumors: a phase 1/2 trial in progress
Phase 3 study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer
Trial in progress: a phase 2, multicenter, single-arm study of zanubrutinib (BGB-3111) in patients with previously treated B-cell malignancies Intolerant to prior treatment with ibrutinib or acalabrutinib
ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: a phase 1B/2 trial-in-progress
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: three years of follow‑up
Résumés
ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM)
Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma
BGB-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress
Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC)
Phase 3 study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC)
Three-year follow-up of treatment-naïve and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib
Trial in progress: A phase III, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma (MCL)
Trial in progress: a phase II, multicenter, single-arm study of zanubrutinib (BGB-3111) in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma intolerant of prior treatment with ibrutinib
Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenström macroglobulinemia (WM)
ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.
Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase II, single-arm, multicenter, study
Mai 2020
International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats) (ISPOR-EU)
International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats) (ISPOR-EU)
Mai 2020 (virtuel)
Résumés
Cost minimization analysis of zanubrutinib for the treatment of adult patients with mantle cell lymphoma who have recieved at least one prior therapy from the payers perspective in the United States
Development of a novel conceptual model to describe the patient reported impact of living with non-small cell lung cancer
Février 2020
American Society of Clinical Oncology - Genitourinary Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers urogénitaux) (ASCO-GU)
American Society of Clinical Oncology - Genitourinary Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers urogénitaux) (ASCO-GU)
Février 2020 (San Francisco, Californie, États-Unis)
Janvier 2020
American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers gastro-intestinaux) (ASCO-GI)
American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers gastro-intestinaux) (ASCO-GI)
Janvier 2020 (San Francisco, Californie, États-Unis)
Posters
Tislelizumab plus chemotherapy as first-line treatment of unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Tislelizumab versus placebo in combination with concurrent chemoradiotherapy in patients with localized esophageal squamous cell carcinoma: a phase 3 trial in progress
Résumés
A phase 3 trial in progress comparing tislelizumab plus concurrent chemoradiotherapy (cCRT) with placebo plus cCRT in patients with localized esophageal squamous cell carcinoma (ESCC)
Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Décembre 2019
European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)
European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)
Décembre 2019 (Genève, Suisse)
Décembre 2019
American Society of Hematology (Société américaine d’hématologie) (ASH)
American Society of Hematology (Société américaine d’hématologie) (ASH)
Décembre 2019 (Orlando, Floride, États-Unis)
Présentations
BTK Leu528Trp - a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia treated with the next generation BTK inhibitor zanubrutinib
Efficacy and safety of zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): initial results from arm C of the SEQUOIA (BGB-3111-304) trial
Treatment with the Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrates high overall response rate and durable responses in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): updated results from a phase 1/2 trial
Posters
A quantitative systems pharmacology (qsp) model to predict receptor occupancy of Bruton's tyrosine kinase (BTK) inhibitors in peripheral blood mononuclear cells, bone marrow and lymph nodes of patients with B-cell malignancies
ALPINE: phase 3 trial of zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
An update on safety and preliminary efficacy of highly specific Bruton tyrosine kinase (BTK) inhibitor zanubrutinib in combination with PD-1 inhibitor tislelizumab in patients with previously treated B-cell lymphoid malignancies
Résumés
A quantitative systems pharmacology (qsp) model to predict receptor occupancy of Bruton's tyrosine kinase (BTK) inhibitors in peripheral blood mononuclear cells, bone marrow and lymph nodes of patients with B-cell malignancies
ALPINE: phase 3 trial of zanubrutinib (BGB-3111) vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
An update on safety and preliminary efficacy of highly specific Bruton tyrosine kinase (BTK) inhibitor zanubrutinib in combination with PD-1 inhibitor tislelizumab in patients with previously treated B-cell lymphoid malignancies
BTK Leu528Trp - a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia treated with the next generation BTK inhibitor zanubrutinib
Efficacy and safety of zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): initial results from Arm C of the SEQUOIA (BGB-3111-304) trial
Exposure-response relationship of the Bruton tyrosine kinase inhibitor, zanubrutinib (BGB-3111) in patients with hematologic malignancies
Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma
Randomized phase 2 zanubrutinib (BGB-3111) + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refractory follicular lymphoma (R/R FL)
Treatment with the Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrates high overall response rate and durable responses in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): updated results from a phase 1/2 trial
Novembre 2019
European Society for Medical Oncology-Asia (Société européenne d’oncologie médicale-Asie) (ESMO-Asie)
European Society for Medical Oncology-Asia (Société européenne d’oncologie médicale-Asie) (ESMO-Asie)
Novembre 2019 (Singapour)
Novembre 2019
Society for Neuro - Oncology (Société de neuro-oncologie) (SNO)
Society for Neuro - Oncology (Société de neuro-oncologie) (SNO)
Novembre 2019 (Phoenix, AZ, États-Unis)
Novembre 2019
International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats - Europe) (ISPOR-EU)
International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats - Europe) (ISPOR-EU)
Novembre 2019 (Copenhague, Danemark)
Septembre 2019
International Workshop on CLL (Atelier international sur la leucémie lymphoïde chronique) (iwCLL)
International Workshop on CLL (Atelier international sur la leucémie lymphoïde chronique) (iwCLL)
Septembre 2019 (Edinburgh, Écosse)
Septembre 2019
Chinese Society of Clinical Oncology (Société chinoise d’oncologie clinique) (CSCO)
Chinese Society of Clinical Oncology (Société chinoise d’oncologie clinique) (CSCO)
Septembre 2019 (Xiamen, Fugian, Chine)
Présentations
Safety and efficacy in patients with long term exposure (LTE) to tislelizumab, an investigational anti PD-1 antibody, in a first in human phase 1 study
Tislelizumab in Chinese patients with esophageal cancer (EC), gastric cancer (GC), hepatocellular carcinoma (HCC), and microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) tumors
Tislelizumab in Chinese patients with melanoma, urothelial carcinoma (UC), and renal cell carcinoma (RCC)
Tislelizumab in Chinese patients with non small cell lung cancer (NSCLC) and nasopharyngeal carcinoma (NPC)
Tislelizumab in combination with chemotherapy as treatment for Chinese patients with esophageal squamous cell carcinoma (ESCC)
Tislelizumab plus chemotherapy as first-line treatment for Chinese patients with lung cancer
Posters
A phase 2 trial in progress to evaluate the efficacy and safety of tislelizumab in Chinese patients with previously treated locally advanced unresctable or metastatic solid tumors with microsatellite instablity-high or mismatch repair deficiency
A phase 3 trial In progress of platinum-containing combination chemotherapy with or without tislelizumab as first-line therapy in patients with untreated extensive-stage small cell lung cancer
Dose escalation of pamiparib in Chinese patients with high-hrade non-mucinous ovarian cancer or advanced triple-negative breast cancer
Pamiparib, an investigational PARP 1/2 inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer harboring germline BRCA 1/2 mutations: an open-label, multicenter, phase 2 trial in China
Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL)
The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (FG/GEJ) adenocarcinoma: RATIONALE 305
Tislelizumab versus placebo in combination with concurrent chemoradiotherapy in patients with localized esophageal squamous cell carcinoma: a phase 3 trial in progress
Zanubrutinib for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
Zanubrutinib, a highly specific BTK inhibitor in Chinese patients with relapsed/refractory B cell malignancies: follow up report of a phase 1 trial in China
Résumés
A phase 1B study to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sitravatinib in combination with tislelizumab in patients (pts) with advanced solid tumors
A phase 2 trial in progress to evaluate the efficacy and safety of tislelizumab in Chinese patients with previously treated locally advanced unresectable or metastatic solid tumors with microsatellite instability-high or mismatch repair deficiency
A phase 3 trial in progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy in Chinese patients with recurrent or metastatic nasopharyngeal cancer
Dose escalation of pamiparib in Chinese patients with high-grade non-mucinous ovarian cancer (HGOC) or advanced triple-negative breast cancer (TNBC)
Pamiparib, an investigational PARP1/2 inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer harboring germline BRCA 1/2 mutations: an open-label, multicenter, phase 2 trial in China
Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL)
Phase 3 study comparing tislelizumab in combination with cisplatin/carboplatin + gemcitabine with placebo in combination with cisplatin/carboplatin + gemcitabine as treatment for Chinese patients with advanced urothelial carcinoma: a trial in progress
Phase 3 trial in progress of platinum-containing combination chemotherapy with or without tislelizumab as first-line therapy in patients with untreated extensive-stage small cell lung cancer (SCLC)
RATIONALE 306: A randomized, placebo-controlled, double-blind trial in progress of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma
Safety and efficacy in patients with long-term exposure (LTE) to tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human phase 1 study
The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab
Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: updated follow-up efficacy and safety results from a phase 2 study
Tislelizumab in Chinese patients (pts) with esophageal cancer (EC), gastric cancer (GC), hepatocellular carcinoma (HCC), and microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) tumors
Tislelizumab in Chinese patients (pts) with non-small cell lung cancer (NSCLC) and nasopharyngeal carcinoma (NPC)
Tislelizumab in Chinese patients with melanoma, urothelial carcinoma (UC), and renal cell carcinoma (RCC)
Tislelizumab in combination with chemotherapy as treatment for Chinese patients with esophageal squamous cell carcinoma (ESCC)
Tislelizumab plus chemotherapy as first-line treatment for Chinese patients with lung cancer
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: RATIONALE 305
Tislelizumab versus placebo in combination with concurrent chemoradiotherapy in patients with localized esophageal squamous cell carcinoma (ESCC): A phase 3 trial in progress
Zanubrutinib for patients with relapsed or refractory chronic lymphocytic leukemia
Zanubrutinib in patients with relapsed/refractory mantle cell lymphoma
Zanubrutinib, a highly specific BTK inhibitor in Chinese patients with relapsed/refractory B-cell malignancies: follow-up report of a phase 1 trial in China
Septembre 2019
World Congress on Lung Cancer (Congrès mondial sur le cancer du poumon) (WCLC)
World Congress on Lung Cancer (Congrès mondial sur le cancer du poumon) (WCLC)
Septembre 2019 (Gran Via, Fira de Barcelona, Espagne)
Septembre 2019
European Society for Medical Oncology (Société européenne d’oncologie médicale) (ESMO)
European Society for Medical Oncology (Société européenne d’oncologie médicale) (ESMO)
Septembre 2019 (Barcelone, Espagne)
Posters
First report of efficacy and safety from a phase 2 trial of tislelizumab, an anti-PD-1 antibody, for the treatment of PD-L1+ locally advanced or metastatic urothelial carcinoma in Asian patients
Population pharmacokinetics of tislelizumab in patients with advanced tumors
Safety, antitumor activity, and pharmacokinetics of pamiparib (BGB-290), a PARP 1/2 inhibitor, in patients with advanced solid tumors: updated phase 1 dose-escalation/expansion results
Tislelizumab exposure-response analysis of efficacy and safety in patients with advanced tumors
Updated results of the PARP 1/2 inhibitor pamiparib in combination with low-dose temozolomide in patients with locally advanced or metastatic solid tumors
Résumés
First report of efficacy and safety from a phase 2 trial of tislelizumab, an anti-PD-1 antibody, for the treatment of PD-L1+ locally advanced or metastatic urothelial carcinoma (UC) in asian patients
Population pharmacokinetics of tislelizumab in patients with advanced tumors
Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results
Tislelizumab exposure-response analyses of efficacy and safety in patients with advanced tumors
Updated results of the PARP 1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours
Juin 2019
International Conference on Malignant Lymphoma (Conférence internationale sur le lymphome malin) (ICML)
International Conference on Malignant Lymphoma (Conférence internationale sur le lymphome malin) (ICML)
Juin 2019 (Lugano, Suisse)
Présentations
Zanubrutinib (BGB-3111) in combination with obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma
Zanubrutinib for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
Zanubrutinib in patients with relapsed or refractory mantle cell lymphoma: a single-arm, multicenter, pivotal phase 2 study
Résumés
Updated safety and efficacy data in the phase 1 trial of patients with mantle cell lyphoma (MCL) treated with Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111)
Zanubrutinib for patients with relapsed or refractory chronic lymphocytic leukemia
Zanubrutinib in patients with relapsed/refractory mantle cell lymphoma
Zanubrutinib plus obinutuzumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relpased/refractory (R/R) follicular lymphoma
Juin 2019
European Hematology Association (Association européenne d’hématologie) (EHA)
European Hematology Association (Association européenne d’hématologie) (EHA)
Juin 2019 (Amsterdam, Pays-Bas)
Posters
Major responses in MYD88 wildtype (MYD88WT) Waldenstrom macroglobulinemia (WM) patients treated with Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111)
Pooled analysis of safety data from monotherapy studies of the Bruton tyrosine kinase (BTK) inhibitor, zanubrutinib (BGB-3111) in B-cell malignancies
Results of tislelizumab monotherapy in Chinese patients with relapsed or refractory classical Hodgkin lymphoma: a single arm, multicenter, pivotal phase 2 study
Updated safety and efficacy data from a cohort of patients with Waldenstrom macroglobulinemia in a phase 1/2 trial treated with the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111)
Résumés
Major responses in MYD88 wildtype (MYD88WT) Waldenstrom macroglobulinemia (WM) in patients treated with Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111)
Pooled anlysis of safety data from monotherapy studies of the Bruton tyrosine kinase (BTK) inhibitor, zanubrutinib (BGB-3111), in B-cell malignancies
Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: updated follow-up efficacy and safety results from a phase 2 study
Updated safety and efficacy data in a phase 1/2 trial of patients with Waldenstrom macroglobulinemia (WM) treated with the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111)
Mai 2019
American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)
American Society of Clinical Oncology (Société américaine d’oncologie clinique) (ASCO)
Mai 2019 (Chicago, Illinois, États-Unis)
Posters
A phase 2 trial in progress: pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer and circulating tumor cell homologous recombination deficiency phenotype or BRCA defects
A phase 3 trial in progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
A randomized, placebo-controlled, phase 3 trial in progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma
ALPINE: phase 3 zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed /refractory chronic lymphocytic leukemia /small lymphocytic lymphoma
Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: a trial in progress
Phase 2 study of zanubrutinib (BGB‑3111) in patients with relapsed /refractory marginal zone lymphoma
Preliminary results with tislelizumab, an investigational anti-PD-1 antibody, in Chinese patients with nasopharyngeal cancer
Résumés
A phase 3 trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
A randomized, placebo-controlled, phase 3 trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
ALPINE: Phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Current treatment patterns and associated outcomes in Waldenström macroglobulinemia (WM) and related hematologic malignancies: a systematic literature review (SLR)
Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: A trial in progress
Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL)
Preliminary results with tislelizumab, an investigational anti-PD-1 antibody, in Chinese patients with nasopharyngeal cancer (NPC)
Randomized phase 2 zanubrutinib (BGB-3111) + obinutuzumab (obi) vs obi monotherapy in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL)
Tislelizumab, an investigational anti-PD-1 antibody, combined with chemotherapy as first-line treatment for lung cancer in Chinese patients
Mai 2019
International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats) (ISPOR-EU)
International Society for Pharmacoeconomics and Outcomes Research - Europe (Société internationale de recherche en pharmacoéconomie et les résultats) (ISPOR-EU)
Mai 2019 (Nouvelle Orléans, Louisiane, États-Unis)
Mars 2019
American Association for Cancer Research (Association américaine de recherche sur le cancer) (AACR)
American Association for Cancer Research (Association américaine de recherche sur le cancer) (AACR)
Mars 2019 (Atlanta, Géorgie, États-Unis)
Posters
A phase 1B study to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors
Long-term exposure (LTE) to tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human phase 1 study
The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab
Résumés
A phase IB study to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors
Long-term exposure (LTE) to tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human phase 1 study
The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab
Février 2019
American Society of Clinical Oncology - Genitourinary Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers urogénitaux) (ASCO-GU)
American Society of Clinical Oncology - Genitourinary Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers urogénitaux) (ASCO-GU)
Février 2019 (San Francisco, Californie, États-Unis)
Janvier 2019
American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers gastro-intestinaux) (ASCO-GI)
American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (Société américaine d’oncologie clinique - Symposium des cancers gastro-intestinaux) (ASCO-GI)
Janvier 2019 (San Francisco, Californie, États-Unis)
Posters
A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer (GC) that responded to platinum-based first-line chemotherapy
Tislelizumab in combination with chemotherapy for the treatment Chinese patients with esophageal squamous cell carcinoma (ESCC): safety and tolerability results from one cohort of an ongoing phase 2 study
Tislelizumab in combination with chemotherapy in Chinese patients with advanced gastric or gastroesophageal junction cancer: results from one cohort of an ongoing phase 2 study
Résumés
A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer (GC) that responded to platinum-based first-line chemotherapy
Tislelizumab in combination with chemotherapy for the treatment of Chinese patients (pts) with esophageal squamous cell carcinoma (ESCC): results from one cohort of an ongoing phase 2 study
Tislelizumab in combination with chemotherapy in Chinese patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer: results from one cohort of an ongoing phase 2 study
Décembre 2018
European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)
European Society of Medical Oncology Immuno-Oncology (Société européenne d’oncologie médicale et d’immuno-oncologie) (ESMO-IO)
Décembre 2018 (Genève, Suisse)